Investors Beware: Hims & Hers Health, Inc. Faces Securities Fraud Investigation – Contact Block & Leviton to Reclaim Your Losses!

Boston, June 23, 2025 — Block & Leviton is looking into possible securities law violations involving Hims & Hers Health, Inc. (NYSE: HIMS). If you’ve lost money on Hims & Hers shares, you can reach out for more information on potential recovery options.

What Happened?

On June 23, shares of Hims & Hers dropped more than 25%. This followed the news that Novo Nordisk ended its partnership with the company. Novo cited “deceptive marketing” and “illegal mass compounding” of semaglutide for weight-loss treatments as reasons for the breakup. They launched their collaboration in April, allowing Hims to sell Wegovy through its telehealth platform. However, Novo claimed Hims continued to market compounded versions of semaglutide even after the FDA had confirmed that Wegovy was no longer in short supply.

Who Can Claim?

Anyone who bought shares of Hims & Hers and has seen their value decline might be eligible for recovery, whether or not they still hold their shares.

What’s Next?

Block & Leviton is investigating the issue to determine if Hims & Hers violated securities laws, and they may take legal action to help investors recover their losses.

Whistleblower Information

If you have inside information about Hims & Hers Health, you might want to share it. Whistleblowers can report to the SEC and stand to gain up to 30% of any recovery from legal actions. Contact Block & Leviton if you have information or questions.

Why Act Now?

Block & Leviton is recognized as a leading securities class-action firm. The team has helped recover billions for investors and is committed to fighting for fair compensation.

Additional Insights

This situation reflects broader trends in healthcare and investor sentiment. The healthcare sector is under increasing scrutiny due to the rapid rise of telehealth and new treatments. In 2025, more than 60% of consumers reported using telehealth services, highlighting its growing importance.

Additionally, surveys show that 75% of investors are more cautious due to regulatory uncertainties in the pharmaceutical industry. This incident with Hims & Hers serves as a reminder for investors to carefully evaluate the companies they support.

For further details about this investigation, you can visit Block & Leviton.

To stay updated on similar issues in the financial landscape, look to reputable sources like the Securities and Exchange Commission for trustworthy information.

Source link

Block & Leviton LLP, $HIMS, HIMS Stock, Novo Nordisk, semaglutide, HIMS securities fraud, Block & Leviton HIMS, HIMS Wegovy, HIMS Fraud, HIMS Class Action, Class Action